Stevo Julius

Q: What Schools Are Affiliated With Stevo Julius

Stevo Julius is affiliated with the following schools: University of Bergen, University of Michigan

Stevo Julius's AcademicInfluence.com Rankings

Stevo Julius

Medical

#1163

World Rank

#1476

Historical Rank

Cardiology

#74

World Rank

#75

Historical Rank

Public Health

#146

World Rank

#153

Historical Rank

Epidemiology

#160

World Rank

#172

Historical Rank

medical Degrees

Stevo Julius

Philosophy

#3951

World Rank

#6292

Historical Rank

Logic

#1523

World Rank

#2296

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Why Is Stevo Julius Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Stevo Julius's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial (1998) (5865)
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol (2002) (5504)
The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. (1997) (2803)
Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial (2004) (2115)
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol (2002) (1631)
Feasibility of treating prehypertension with an angiotensin-receptor blocker. (2006) (894)
Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. (2005) (666)
Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial (2004) (612)
Reduction in Albuminuria Translates to Reduction in Cardiovascular Events in Hypertensive Patients: Losartan Intervention for Endpoint Reduction in Hypertension Study (2005) (603)
Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The value randomised trial☆ (2004) (599)
Albuminuria and Cardiovascular Risk in Hypertensive Patients with Left Ventricular Hypertrophy: The LIFE Study (2003) (598)
Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. (2004) (574)
Mild high-renin essential hypertension. Neurogenic human hypertension? (1977) (542)
Heart rate and the cardiovascular risk (1997) (511)
Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. (2002) (469)
Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (2002) (416)
The sympathetic nervous system and the metabolic syndrome. (2007) (369)
Role of Parasympathetic Inhibition in the Hyperkinetic Type of Borderline Hypertension (1971) (359)
The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group. (1997) (356)
1993 Guidelines for the Management of Mild Hypertension: Memorandum From a World Health Organization/ International Society of Hypertension Meeting (1993) (348)
Reflex sympathetic activation induces acute insulin resistance in the human forearm. (1993) (304)
“White Coat” Versus “Sustained” Borderline Hypertension in Tecumseh, Michigan (1990) (303)
Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension. (1998) (302)
Autonomic nervous cardiovascular regulation in borderline hypertension. (1975) (294)
Elevated Heart Rate: A Major Risk Factor for Cardiovascular Disease (2004) (287)
The association of borderline hypertension with target organ changes and higher coronary risk. Tecumseh Blood Pressure study. (1990) (281)
Influence of Age on the Hemodynamic Response to Exercise (1967) (279)
Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. (2006) (278)
High heart rate: a risk factor for cardiovascular death in elderly men. (1999) (276)
Regression of Electrocardiographic Left Ventricular Hypertrophy by Losartan Versus Atenolol: The Losartan Intervention For Endpoint reduction in hypertension (LIFE) Study (2003) (274)
Hemodynamic Studies in Patients with Borderline Blood Pressure Elevation (1968) (261)
The hemodynamic link between insulin resistance and hypertension. (1991) (259)
Borderline hypertension--a critical review. (1971) (258)
Overweight and hypertension : a 2-way street? (2000) (253)
Type II Diabetes, Essential Hypertension, and Obesity as "Syndromes of Impaired Genetic Homeostasis": The "Thrifty Genotype" Hypothesis Enters the 21st Century (2015) (252)
Autonomic imbalance, hypertension, and cardiovascular risk. (2000) (248)
Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. (2005) (240)
Hyperkinetic borderline hypertension in Tecumseh, Michigan (1991) (236)
Sympathetic overactivity in hypertension. A moving target. (1996) (234)
Corcoran Lecture. Sympathetic hyperactivity and coronary risk in hypertension. (1993) (226)
Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial (2008) (224)
Identification and management of the hypertensive patient with elevated heart rate: statement of a European Society of Hypertension Consensus Meeting. (2006) (223)
The role of cardiac autonomic function in hypertension and cardiovascular disease (2009) (194)
Sex‐Specific Determinants of Increased Left Ventricular Mass in the Tecumseh Blood Pressure Study (1994) (190)
Mechanism of increased alpha adrenergic vasoconstriction in human essential hypertension. (1987) (189)
Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138 769 individuals (2011) (189)
Relationship Between Cardiac Output and Peripheral Resistance in Borderline Hypertension (1971) (180)
Relationship of tachycardia with high blood pressure and metabolic abnormalities: a study with mixture analysis in three populations. (1997) (175)
Blood pressure crisis following withdrawal of clonidine (Catapres, Catapresan), with special reference to arterial and urinary catecholamine levels, and suggestions for acute management. (1973) (168)
The 1993 guidelines for the management of mild hypertension: memorandum from a WHO/ISH meeting. (1993) (165)
Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial (2006) (165)
Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial (2006) (165)
H35: Baseline characteristics of the life (Losartan intervention for endpoint reduction) in hypertension study (1997) (161)
The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design. (1998) (159)
Reference values for self-recorded blood pressure: a meta-analysis of summary data. (1998) (156)
The interconnection between sympathetics, microcirculation, and insulin resistance in hypertension. (1992) (156)
1993 guidelines for the management of mild hypertension: memorandum from a WHO/ISH meeting. (1993) (152)
The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) Trial: Outcomes in Patients Receiving Monotherapy (2006) (148)
The blood pressure seeking properties of the central nervous system. (1988) (148)
Anger and anxiety in borderline hypertension. (1986) (142)
Altered Cardiac Responsiveness and Regulation in the Normal Cardiac Output Type of Borderline Hypertension (1975) (141)
Impact of new-onset diabetes mellitus on development of atrial fibrillation and heart failure in high-risk hypertension (from the VALUE Trial). (2008) (139)
Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy (2004) (139)
Sympathetics, insulin resistance and coronary risk in hypertension: the 'chicken-and-egg' question. (1994) (138)
Autonomic nervous system dysregulation in human hypertension. (1991) (138)
Blood pressure variability and risk of cardiovascular events and death in patients with hypertension and different baseline risks (2018) (137)
Home blood pressure determination. Value in borderline ("labile") hypertension. (1974) (136)
Benefits and risks of more intensive blood pressure lowering in hypertensive patients of the HOT study with different risk profiles: does a J-shaped curve exist in smokers? (2003) (133)
Hemodynamic effects of acute and prolonged beta-adrenergic blockade in essential hypertension. (2009) (129)
Baseline Characteristics in Relation to Electrocardiographic Left Ventricular Hypertrophy in Hypertensive Patients: The Losartan Intervention For Endpoint Reduction (LIFE) in Hypertension Study (2000) (128)
Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: the LIFE study. (2004) (128)
Electrocardiographic Strain Pattern and Prediction of Cardiovascular Morbidity and Mortality in Hypertensive Patients (2004) (126)
Risk/Benefit Assessment of &bgr;-Blockers and Diuretics Precludes Their Use for First-Line Therapy in Hypertension (2008) (123)
Abnormalities of plasma volume in borderline hypertension. (1971) (122)
Association of tachycardia with morbidity and mortality: pathophysiological considerations. (1997) (121)
Usefulness of heart rate to predict cardiac events in treated patients with high-risk systemic hypertension. (2012) (111)
Plasma Norepinephrine Variations with Dietary Sodium Intake (1980) (110)
SUPPRESSION OF SYMPATHETIC NERVOUS FUNCTION IN LOW-RENIN ESSENTIAL HYPERTENSION (1976) (110)
Racial differences in erythrocyte cation transport. (1984) (110)
The changing face of sympathetic overactivity in hypertension (2000) (106)
Influence of Hypertension on the Hemodynamic Response to Exercise (1967) (106)
Stroke Reduction in Hypertensive Adults With Cardiac Hypertrophy Randomized to Losartan Versus Atenolol: The Losartan Intervention For Endpoint Reduction in Hypertension Study (2005) (100)
Regression of Electrocardiographic Left Ventricular Hypertrophy Is Associated with Less Hospitalization for Heart Failure in Hypertensive Patients (2007) (98)
The evidence for a pathophysiologic significance of the sympathetic overactivity in hypertension. (1996) (98)
Transition from high cardiac output to elevated vascular resistance in hypertension. (1988) (96)
Relationship of the electrocardiographic strain pattern to left ventricular structure and function in hypertensive patients: the LIFE study. Losartan Intervention For End point. (2001) (96)
Summary of 1993 World Health Organisation-International Society of Hypertension guidelines for the management of mild hypertension. Subcommittee of WHO/ISH Mild Hypertension Liaison committee. (1993) (95)
All-cause and cardiovascular mortality in relation to changing heart rate during treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy. (2010) (94)
Impact of New-Onset Diabetes Mellitus on Cardiac Outcomes in the Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) Trial Population (2007) (94)
PERSONALITY TRAITS AND BEHAVIORAL PATTERNS ASSOCIATED WITH SYSTOLIC BLOOD PRESSURE LEVELS IN COLLEGE MALES. (1964) (92)
Laboratory Studies Neurogenic Pressor Episodes Fail To Cause Hypertension, But Do Induce Cardiac Hypertrophy (1989) (92)
Comparison of cardiac output determined by CO2 rebreathing and dye-dilution methods (1968) (91)
Impact of Increased Heart Rate on Clinical Outcomes in Hypertension (2012) (89)
VALUE trial: Long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk (2003) (88)
Cardiovascular outcomes at different on-treatment blood pressures in the hypertensive patients of the VALUE trial. (2016) (87)
Characteristics of 15314 Hypertensive Patients at High Coronary Risk. The VALUE Trial (2001) (86)
SYMPATHETIC OVERACTIVITY AND CORONARY RISK IN HYPERTENSION (1997) (86)
Benefit and harm of low-dose aspirin in well-treated hypertensives at different baseline cardiovascular risk (2002) (85)
Ethnic differences in electrocardiographic criteria for left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint. (2002) (84)
Lead, hypertension, and the renin-angiotensin system in rats. (1982) (83)
Relation of renin status to neurogenic vascular resistance in borderline hypertension. (1975) (83)
Impact of Diabetes Mellitus on Regression of Electrocardiographic Left Ventricular Hypertrophy and the Prediction of Outcome During Antihypertensive Therapy: The Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study (2006) (82)
Sympathetic Overactivity in Hypertension (1997) (79)
PREDICTORS OF HYPERTENSION (1978) (78)
Hypertension optimal treatment (HOT) study: home blood pressure in treated hypertensive subjects. (1998) (77)
Role of central blood volume in hyperkinetic borderline hypertension. (1973) (76)
Renin response to stimulation of cardiopulmonary mechanoreceptors in man. (1978) (75)
Effects of Losartan or Atenolol in Hypertensive Patients without Clinically Evident Vascular Disease: A Substudy of the LIFE Randomized Trial (2003) (75)
Role of the autonomic nervous system in mild human hypertension. (1975) (75)
Relationships between metrics of visit-to-visit variability of blood pressure (2013) (74)
Clinical Effect of Naturally Random Allocation to Lower Systolic Blood Pressure Beginning Before the Development of Hypertension (2014) (72)
Management of the hypertensive patient with elevated heart rate: Statement of the Second Consensus Conference endorsed by the European Society of Hypertension. (2016) (69)
The role of the autonomic nervous system in hypertension. (1995) (69)
Prediction of cardiovascular outcome by estimated glomerular filtration rate and estimated creatinine clearance in the high-risk hypertension population of the VALUE trial (2007) (68)
The physiological determinants and risk correlations of elevated heart rate. (1999) (68)
Effect of sympathetic overactivity on cardiovascular prognosis in hypertension. (1998) (68)
The international database of self-recorded blood pressures in normotensive and untreated hypertensive subjects. (1999) (68)
Hemodynamic Responses to Tilt and Beta‐Adrenergic Blockade in Young Patients with Borderline Hypertension (1970) (67)
Blood Pressure Measurement Device, Number and Timing of Visits, and Intra‐Individual Visit‐to‐Visit Variability of Blood Pressure (2012) (66)
Incidence of Atrial Fibrillation in Relation to Changing Heart Rate Over Time in Hypertensive Patients: The LIFE Study (2006) (65)
The Tecumseh Blood Pressure Study. Normative data on blood pressure self-determination. (1990) (65)
Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy (2005) (65)
Home blood pressure monitoring. (2000) (64)
Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. (2004) (64)
Relationship of age and blood pressure to baroreflex sensitivity and arterial compliance in man. (1976) (63)
Sympathetic Hyperactivity in Early Stages of Hypertension: The Ann Arbor Data Set (1988) (63)
Reflex‐Hemodynamic Adjustments and Baroreflex Sensitivity During Converting Enzyme Inhibition with MK‐421 in Normal Humans (1983) (61)
Treatment of mild hypertension with progressive muscle relaxation. Predictive value of indexes of sympathetic tone. (1984) (60)
Trial of preventing hypertension: design and 2-year progress report. (2004) (59)
Rationale, Design, and Methods (1997) (58)
Amlodipine in hypertension: an overview of the clinical dossier. (1988) (58)
Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. (2004) (58)
Increased platelet catecholamine content in pheochromocytoma: a diagnostic test in patients with elevated plasma catecholamines. (1982) (57)
Home blood pressure as a predictor of future blood pressure stability in borderline hypertension. The Tecumseh Study. (1997) (57)
Analysis of design and reactivity of series-coupled vascular sections in spontaneously hypertensive rats (SHR). (1974) (57)
No evidence for a J-shaped curve in treated hypertensive patients with increased cardiovascular risk: The VALUE trial (2016) (57)
Relation of echocardiographic left ventricular mass and hypertrophy to persistent electrocardiographic left ventricular hypertrophy in hypertensive patients: the LIFE Study. (2001) (56)
Changing role of the autonomic nervous system in human hypertension. (1990) (56)
Behavior, blood pressure variability, and hypertension. (1985) (54)
Usefulness of home BP determination in treating borderline hypertension. (1982) (54)
Metabolic syndrome and insulin resistance in the TROPHY sub-study: contrasting views in patients with high-normal blood pressure. (2005) (54)
Vasoconstriction with norepinephrine causes less forearm insulin resistance than a reflex sympathetic vasoconstriction. (1994) (53)
Consequences of the increased autonomic nervous drive in hypertension, heart failure and diabetes. (1998) (53)
The role of stress in hypertension. (1979) (53)
Regression of electrocardiographic left ventricular hypertrophy predicts regression of echocardiographic left ventricular mass: the LIFE study (2004) (53)
VALUE trial: Long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk. (2004) (52)
White coat hypertension: a follow-up. (1992) (52)
Effect of Beta-Adrenergic Blockade on Plasma Volume in Human Subjects 1 (1972) (52)
Propranolol therapy in essential hypertension. Observations on predictability of therapeutic response. (1974) (52)
Effect of circulating epinephrine on platelet function and hematocrit. (1995) (51)
RELATION BETWEEN CASUAL BLOOD PRESSURE READINGS IN YOUTH AND AT AGE 40: A RETROSPECTIVE STUDY. (1964) (50)
Early Association of Sympathetic Overactivity, Hypertension, Insulin Resistance, and Coronary Risk (1992) (50)
Agreement among three different indices of sympathetic nervous system activity in essential hypertension. (1977) (50)
The fifth scientific meeting of the interamerican society of hypertension, 1983 (1983) (50)
Systemic haemodynamics in borderline arterial hypertension: responses to static exercise before and under the influence of propranolol. (1972) (49)
Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint. (2000) (49)
Determinants of baroreflex sensitivity in man. (1978) (48)
Antihypertensive and hypotensive effects of atrial natriuretic factor in men. (1987) (48)
Antihypertensive treatment of patients with diabetes and hypertension. (2001) (48)
Stroke volume--pulse pressure relationships in borderline hypertension: a possible indicator of decreased arterial compliance. (1984) (48)
Medical Therapies for Heart Failure With Preserved Ejection Fraction. (2019) (47)
Home Blood Pressure Monitoring. Current Knowledge and Directions for Future Research (2001) (46)
HOME BLOOD-PRESSURE RECORDING (1975) (45)
Hematocrit levels and physiologic factors in relationship to cardiovascular risk in Tecumseh, Michigan (1994) (45)
Isolated systolic hypertension in the young: a position paper endorsed by the European Society of Hypertension (2018) (44)
Angiotensin mediates forearm glucose uptake by hemodynamic rather than direct effects. (1996) (44)
Abnormalities of autonomic nervous control in human hypertension (1994) (43)
The determinants of plasma-renin activity in essential hypertension. (1978) (43)
Relative influence of insulin resistance versus blood pressure on vascular changes in longstanding hypertension. ICARUS, a LIFE sub study (2000) (42)
Borderline hypertension. An overview. (1977) (41)
The effect of baseline physical activity on cardiovascular outcomes and new‐onset diabetes in patients treated for hypertension and left ventricular hypertrophy: the LIFE study (2007) (41)
Autonomic Nervous Dysfunction in Essential Hypertension (1991) (41)
The complex interaction between overweight, hypertension, and sympathetic overactivity. (2009) (41)
1989 guidelines for the management of mild hypertension: memorandum from a WHO/ISH meeting. (1989) (41)
Arterial pressure, cardiac output and systemic resistance before and after pithing in normotensive and spontaneously hypertensive rats. (1975) (39)
Effect of beta adrenoceptor antagonists on baroreceptor reflex sensitivity in hypertension (1977) (39)
The defense reaction: a common denominator of coronary risk and blood pressure in neurogenic hypertension? (1995) (39)
Gender Differences in Regression of Electrocardiographic Left Ventricular Hypertrophy During Antihypertensive Therapy (2008) (38)
Body Build and Risk of Cardiovascular Events in Hypertension and Left Ventricular Hypertrophy: The LIFE (Losartan Intervention For Endpoint reduction in hypertension) Study (2005) (38)
Characteristics of 15,314 hypertensive patients at high coronary risk. The VALUE trial. The Valsartan Antihypertensive Long-term Use Evaluation. (2001) (38)
Smoking is associated with higher cardiovascular risk in young women than in men: the Tecumseh Blood Pressure Study (1997) (37)
Antihypertensive Utility of Perindopril in a Large, General Practice‐Based Clinical Trial (2004) (37)
Platelet Function During Antihypertensive Treatment with Quinapril, a Novel Angiotensin Converting Enzyme Inhibitor (1991) (37)
The Effects of Losartan Compared to Atenolol on Stroke in Patients With Isolated Systolic Hypertension and Left Ventricular Hypertrophy. The LIFE Study (2005) (37)
TROPHY study: Outcomes based on the Seventh Report of the Joint National Committee on Hypertension definition of hypertension. (2008) (37)
Stress, autonomic hyperactivity and essential hypertension: an enigma. (1985) (37)
PSYCHOLOGICAL CORRELATES OF BLOOD PRESSURE. (1964) (36)
Pulse Pressure and Effects of Losartan or Atenolol in Patients With Hypertension and Left Ventricular Hypertrophy (2005) (36)
Syndrome X: Is it for real? (1998) (35)
Personality, elevated blood pressure, and essential hypertension (1992) (35)
Ambulatory blood pressure monitoring and laboratory reactivity in type A behavior and components. (1989) (35)
Sustained Blood Pressure Elevation to Lower Body Compression in Pigs and Dogs (1982) (35)
Tachycardia: an important determinant of coronary risk in hypertension. (1998) (35)
Blood pressure measurement in research (2002) (35)
Blood pressure elevation during hindquarter compression in dogs is neurogenic. (1984) (35)
Home blood pressure monitoring: advantages and limitations. (1991) (34)
Is low-risk hypertension fact or fiction? cardiovascular risk profile in the TROPHY study. (2005) (34)
Predictors of cardiovascular events in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study (2009) (34)
Anxiety and cardiovascular reactivity in the Tecumseh population (1998) (34)
Independence of pressure reactivity from pressure levels in Tecumseh, Michigan. (1991) (33)
Attenuation of haemodynamic, metabolic and energy expenditure responses to isoproterenol in patients with hypertension (2004) (33)
Cardiovascular outcomes in hypertensive patients: comparing single-agent therapy with combination therapy (2012) (32)
Disease entities, mixed multi-normal distributions, and the role of the hyperkinetic state in the pathogenesis of hypertension. (1990) (31)
Effects of increased arterial epinephrine on insulin, glucose and phosphate. (1996) (31)
Of rat and man. (2003) (30)
Hemodynamic and Neurohumoral Evidence of Multifaceted Pathophysiology in Human Hypertension (1990) (30)
Role of cardiopulmonary mechanoreceptors in ADH release in normal humans. (1984) (30)
Prehypertension: Risk stratification and management considerations (2008) (30)
Interaction between renin and the autonomic nervous system in hypertension. (1988) (30)
A "gender blind" relationship of lean body mass and blood pressure in the Tecumseh study. (2002) (30)
Alcohol consumption and cardiovascular risk in hypertensives with left ventricular hypertrophy: the LIFE study (2004) (29)
Relevance of heart rate as a risk factor in hypertension (1999) (29)
The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) study. (2005) (29)
Physician (investigator) inertia in apparent treatment-resistant hypertension – Insights from large randomized clinical trials. Lennart Hansson Memorial Lecture (2015) (29)
Ambulatory blood pressure monitoring after 1 year on valsartan or amlodipine-based treatment: a VALUE substudy (2007) (29)
The VALUE Trial (2005) (28)
Role of cardiac factors in the initial hypotensive action by beta-adrenoreceptor blocking agents. (1984) (28)
Predictors of new-onset diabetes mellitus in hypertensive patients: the VALUE trial (2008) (28)
Racial differences in sudden cardiac death among hypertensive patients during antihypertensive therapy: the LIFE study. (2012) (26)
Increased central blood volume: a poosible pathophysiological factor im mild low-renin essential hypertension. (1976) (26)
Practical utility of blood pressure readings obtained by self-determination. (1989) (26)
Effect of changing heart rate during treatment of hypertension on incidence of heart failure. (2012) (26)
The impact of serum uric acid on cardiovascular outcomes in the LIFE study. (2004) (25)
Parental hyperdynamic circulation predicts insulin resistance in offspring: The Tecumseh Offspring Study. (1999) (25)
Vascular hypertrophy in borderline hypertension: relationship to blood pressure and sympathetic drive. (1985) (25)
Home Blood Pressure as a Predictor of Future Blood Pressure Stability in Borderline Hypertension (1997) (25)
Clinical experience with perindopril in African-American hypertensive patients: a large United States community trial. (2004) (25)
COMPARISON OF VARIOUS CLINICAL MEASUREMENTS OF BLOOD PRESSURE WITH THE SELF-DETERMINATION TECHNIQUE IN NORMOTENSIVE COLLEGE MALES. (1964) (25)
Role of cardiovascular receptors on the neural regulation of renin release in normal men. (1983) (25)
Prehypertension: A possible target for antihypertensive medication (2000) (24)
The ALLHAT study: if you believe in evidence-based medicine, stick to it! (2003) (24)
Genetic contribution to the variance in left ventricular mass: the Tecumseh Offspring Study. (2001) (23)
EVIDENCE AGAINST AN INTERACTION OF ANGIOTENSIN II WITH THE SYMPATHETIC NERVOUS SYSTEM IN MAN (1981) (23)
Letter: Home blood-pressure recording. (1975) (23)
Decreased Venous Distensibility and Reduced Renin Responsiveness in Hypertension (1986) (23)
Sympathetic Nervous System Involvement in Essential Hypertension: Increased Platelet Noradrenaline Coincides with Decreased β-Adrenoreceptor Responsiveness (1994) (23)
Quinapril, an Angiotensin Converting Enzyme Inhibitor, Prevents Cardiac Hypertrophy During Episodic Hypertension (1991) (23)
Determinants of left ventricular structure and mass in young subjects with sympathetic over‐activity. The Tecumseh Offspring Study (2000) (22)
Brain and the regulation of blood pressure: a hemodynamic perspective. (1989) (22)
Clinical and physiological significance of borderline hypertension at youth. (1978) (22)
Research utility of noninvasive methods for measurement of cardiac output (1987) (21)
Review: Prehypertension: should we be treating with pharmacologic therapy? (2008) (21)
Evaluation of self-measured home vs. clinic intra-arterial blood pressure. (1993) (21)
A Bayesian model for time-to-event data with informative censoring. (2012) (20)
Losartan benefits over atenolol in non‐smoking hypertensive patients with left ventricular hypertrophy: The LIFE study (2004) (20)
Combination of the electrocardiographic strain pattern and albuminuria for the prediction of new-onset heart failure in hypertensive patients: the LIFE study. (2008) (20)
Long-Term Potential of Angiotensin Receptor Blockade for Cardiovascular Protection in Hypertension: The VALUE Trial (1999) (20)
Antihypertensive and β‐adrenoceptor antagonist action of timolol (1978) (20)
Mechanism of Angiotensin II Type 1 Receptor Blocker Action in the Regression of Left Ventricular Hypertrophy (2006) (20)
Hemodynamic effects of angiotensin-converting enzyme inhibitors in essential hypertension: a review. (1985) (20)
Questions and answers on hypertension. (1971) (19)
Pharmacologic reduction of sympathetic drive increases platelet alpha‐2–receptor number (1985) (19)
Efficacy of an oral angiotensin-converting enzyme inhibitor (captopril) in severe hypertension. (1981) (19)
New markers for type A behavior: pupil size and platelet epinephrine. (1987) (18)
Cardiopulmonary mechanoreceptors and renin release in humans. (1983) (18)
Predictors of blood pressure and hypertension. General principles. (1991) (17)
Correlates of the estimated arterial compliance in the population of Tecumseh, Michigan. (1992) (17)
IX - 1993 Guidelines for management of mild hypertension. Memorandum from a WHO/ISH meeting (1993) (17)
An Evaluation of the Effects of an Angiotensin Receptor Blocker on Health‐Related Quality of Life in Patients With High‐Normal Blood Pressure (Prehypertension) in the Trial of Preventing Hypertension (TROPHY) (2008) (17)
Clinical implications of pathophysiologic changes in the midlife hypertensive patient. (1991) (17)
Five decades of antihypertensive treatment: the unresolved issues. (2000) (17)
Comparison of guanadrel and guanethidine (1973) (17)
Borderline hypertension. Hypertension seminars at Ostra Hospital, Göteberg, Sweden. (2009) (17)
Linkage of MN Locus and Erythrocyte Lithium‐Sodium Countertransport in Tecumseh, Michigan (1991) (17)
Current trends in the treatment of hypertension: a mixed picture. (1997) (17)
Abnormalities of autonomic nervous control in borderline hypertension. (1976) (17)
The nervous system in arterial hypertension : [proceedings] (1976) (16)
Worldwide trends and shortcomings in the treatment of hypertension. (2000) (16)
The psychophysiology of borderline hypertension. (1981) (16)
Clinical consequences of the autonomic imbalance in hypertension and congestive heart failure. (1998) (16)
Are left ventricular mass, geometry and function related to vascular changes and/or insulin resistance in long-standing hypertension? ICARUS: a LIFE substudy (2003) (16)
High-renin essential hypertension: adrenergic cardiovascular correlates. (1976) (16)
Feasibility of regression of hypertension using contemporary antihypertensive agents. (2013) (16)
Effect of home blood pressure and gender on estimates of the familial aggregation of blood pressure. The Tecumseh Blood Pressure Study. (1992) (16)
Red blood cell Li+-Na+ countertransport, Na+-K+ cotransport, and the hemodynamics of hypertension. (1987) (15)
Red Blood Cell Lithium‐Sodium Countertransport in the Tecumseh Blood Pressure Study (1991) (15)
Progressive effects of valsartan compared with amlodipine in prevention of diabetes according to categories of diabetogenic risk in hypertensive patients: The VALUE trial (2008) (15)
A Bayesian sensitivity model for intention‐to‐treat analysis on binary outcomes with dropouts (2009) (15)
Predictors of blood pressure and hypertension in Tecumseh, Michigan. (1990) (15)
Contrasting effects of epinephrine on forearm hemodynamics and arterial plasma norepinephrine. (1993) (15)
Effects of ketanserin on blood pressure and platelet aggregation in elderly men with mild hypertension. (1988) (14)
Changes in left ventricular diastolic filling during the development of left ventricular hypertrophy: observations using Doppler echocardiography in a unique canine model. (1991) (14)
Behavioral factors in hypertension (1987) (14)
Coronary disease in hypertension: a new mosaic. (1997) (14)
Heart rate as a predictor of stroke in high-risk, hypertensive patients with previous stroke or transient ischemic attack. (2014) (14)
Behaviour and hypertension: a pathophysiological puzzle (1989) (14)
Cardiovascular morbidity and mortality in hypertensive patients with atrial fibrillation: The LIFE study (2003) (13)
Short term effectiveness and hemodynamic actions of guanadrel, a new sympatholytic drug. (1972) (12)
Tachycardia in hypertension: a saga of progress despite prejudice, confusion, and inertia. (2009) (12)
The Short Treatment with the Angiotensin Receptor Blocker Candesartan Surveyed by Telemedicine (STAR CAST) Study: Rationale and Study Design (2008) (12)
Role of the sympathetic nervous system in the pathophysiology of cardiovascular disease. (1987) (12)
Are different hemodynamic patterns of antihypertensive drugs clinically important? (1990) (11)
Heritability of left atrial size in the Tecumseh population (2002) (11)
Hemodynamics of prehypertension and hypertension. (1974) (11)
The Hypertension Optimal Treatment (HOT) Study in the United States. (1996) (11)
BLOOD PRESSURE REACTIVITY AND RECALL OF TREATMENT BY PARENTS. (1965) (11)
The emerging field of borderline hypertension. (1986) (11)
Pharmacologic tools for assessment of adrenergic nerve activity in human hypertension. (1984) (10)
Angiotensin-receptor blockade, cancer, and concerns. (2010) (10)
Should the results of TROPHY affect the JNC 7 definition of prehypertension? (2007) (10)
Validation of non-invasive measurement of cardiac output. The Ann Arbor experience. (1990) (10)
In prehypertension leukocytosis is associated with body mass index but not with blood pressure or incident hypertension (2014) (10)
Hemodynamic effects of quinapril, a novel angiotensin‐converting enzyme inhibitor (1990) (10)
Smoking and overweight associated with masked uncontrolled hypertension: a Hypertension Optimal Treatment (HOT) Sub-Study (2020) (9)
A double-blind, randomized study evaluating losartan potassium monotherapy or in combination with hydrochlorothiazide versus placebo in obese patients with hypertension* (2008) (9)
Neurogenic maintenance of peripheral resistance in borderline hypertension. (1974) (9)
Role of the Nervous System in Human Hypertension (2001) (9)
Antihypertensive and beta-adrenoceptor antagonist action of timolol. (1978) (8)
THE PLACE OF METHYLDOPA IN THE TREATMENT OF SEVERE HYPERTENSION. (1963) (8)
Can hypertension be prevented? The Danish Hypertension Prevention Project and the Trial of Prevention of Hypertension studies. (2002) (8)
Vasodilators in the treatment of hypertension. (1982) (8)
Lennart Hansson, MD (2003) (8)
Resting heart rate: an independent predictor of congestive heart failure. (2014) (8)
Borderline hypertension: clinical and pathophysiologic significance. (1978) (8)
Baroreflex sensitivity during converting enzyme inhibition with enalapril (MK-421) in normal man (1983) (7)
Racial differences in incident atrial fibrillation among hypertensive patients during antihypertensive therapy. (2014) (7)
Blood pressure lowering only or more? Has the jury reached its verdict? (2007) (7)
Hemodynamic plasticity during hindquarter compression. (1988) (7)
A New Dimension in Hypertension: Role of Insulin Resistance (1990) (7)
Sympathetic nervous system involvement in essential hypertension: increased platelet noradrenaline coincides with decreased beta-adrenoreceptor responsiveness. (1994) (7)
Role of cardiopulmonary mechanoreceptors in the postural regulation of renin. (1987) (7)
Role of sympathetic overactivity in the pathophysiology of the metabolic syndrome (2004) (7)
Role of sympathetic overactivity in the pathophysiology of the metabolic syndrome (2004) (7)
Long-term plasma catecholamines in patients with hypertension and left ventricular hypertrophy treated with losartan or atenolol: ICARUS, a LIFE substudy (2004) (6)
Sympathetic nervous system as a coronary risk factor in hypertension. (1996) (6)
Blood Pressure–Lowering Profiles and Clinical Effects of Angiotensin Receptor Blockers Versus Calcium Channel Blockers (2020) (6)
Borderline hypertension: significance and management. (1978) (6)
Hemodynamic and pharmacologic correlates of plasma norepinephrine in hypertension (1984) (6)
Effect of systemic autonomic inhibition on the hemodynamic response to antihypertensive therapy with timolol. (1979) (6)
Trends in left ventricular function over three years in the Tecumseh Study. (1997) (6)
Consequences of the evolutionary cardiovascular challenge of human bipedalism: orthostatic intolerance syndromes, orthostatic hypertension. (2019) (6)
Trials of antihypertensive treatment--new agenda for the millennium. (2000) (6)
Does blood pressure reduction necessarily compromise cardiac function or renal hemodynamics? Effects of the angiotensin-converting enzyme inhibitor quinapril. (1992) (6)
The association of tachycardia with obesity and elevated blood pressure. (2002) (6)
Recreational exercise and cardiovascular status in the rural community of Tecumseh, Michigan. (1994) (5)
Assessment of autonomic nervous function in human hypertension (1992) (5)
One year of antihypertensive treatment in patients with LVH: the life study. (1999) (5)
Insulin, insulin resistance, and blood pressure elevation. (1993) (5)
The heart and the regulation of renin. (1987) (5)
University of California, Davis, conference: Mild hypertension. (1988) (5)
Increased beta-adrenergic tone enhances arterial compliance in hyperkinetic borderline hypertension. (1989) (5)
Association of left bundle branch block with cardiovascular morbidity and mortality in hypertensive patients with left ventricle hypertrophy: the life study (2004) (5)
Long‐Term Effects of a Losartan‐Compared With an Atenolol‐Based Treatment Regimen on Carotid Artery Plaque Development in Hypertensive Patients With Left Ventricular Hypertrophy: ICARUS, a LIFE Substudy (2006) (5)
A double-blind, randomized study evaluating losartan potassium monotherapy or in combination with hydrochlorothiazide versus placebo in obese patients with hypertension. (2008) (5)
Chapter 33 – Main Results from VALUE (2005) (5)
TACHYCARDIA IS A STRONG PREDICTOR OF CARDIOVASCULAR EVENTS IN THE VALUE TRIAL: 6A.04 (2010) (4)
Cardiovascular outcomes at recommended blood pressure targets in middle-aged and elderly patients with type 2 diabetes mellitus compared to all middle-aged and elderly hypertensive study patients with high cardiovascular risk (2021) (4)
3D.01: VISIT-TO-VISIT BLOOD PRESSURE VARIABILITY INCREASES RISK OF STROKE OR CARDIAC EVENTS IN PATIENTS GIVEN VALSARTAN OR AMLODIPINE IN THE VALUE TRIAL (2015) (4)
Borderline hypertension. (2020) (4)
812-4 Serum uric acid and ischemic stroke risk among hypertensive patients with left ventricular hypertrophy: The losartan intervention for endpoint reduction in hypertension (LIFE) study (2004) (4)
Optimizing the assessment of the elderly patient with borderline hypertension: The Hypertension and Ambulatory Recording in the OLD (HAROLD) study (1997) (4)
OR-27: The interaction between aspirin and losartan on cardiovascular morbidity and mortality in patients with hypertension and left ventricular hypertrophy. A losartan intervention for endpoint reduction (LIFE) substudy (2003) (4)
THE VALSARTAN ANTIHYPERTENSIVE LONGTERM USE EVALUATION (VALUE) TRIAL: FINAL PATIENTS DEMOGRAPHICS (2000) (4)
Clinical Experience with Perindopril in Elderly Hypertensive Patients (2004) (4)
Easy money?: Health cost savings resulting from the switch from a branded drug to a low‐cost generic drug in the same class (2011) (4)
THE EFFECT OF HYPERTENSIVE EPISODES AND CARDIAC HYPERTROPHY ON THE CANINE CARDIAC BAROREFLEX (1994) (4)
Reliability of echocardiography in assessing cardiac output (1981) (4)
The challenge of very mild hypertension: should treatment be sooner or later? (1998) (3)
Regression of echocardiographic left ventricular hypertrophy in relation to resolution versus persistence of electrocardiographic strain after one year of antihypertensive therapy The LIFE study (2002) (3)
[Stimulation of the sinus nerves with an implanted baropacer in patients with therapy-resistant hypertension]. (1973) (3)
Hemodynamic Assessment and Pharmacologic Probes as Tools to Analyze Cardiovascular Reactivity (1989) (3)
Neither Red Nor Dead: Coming of Age in Former Yugoslavia During and After World War II (2003) (3)
Gender differences in regression of electrocardiographic left ventricular hypertrophy in response to antihypertensive therapy: The LIFE study (2003) (3)
The authors reply [5] (2006) (3)
DETERMINANTS OF THE NEW DEVELOPMENT OF LEFT VENTRICULAR HYPERTROPHY ON TREATED HYPERTENSIVES: THE VALUE-TRIAL (2004) (3)
Office and out of office heart rate measurements: which clinical value? (2008) (3)
Controversies in the Research on Hemodynamic Mechanisms in the Development of Hypertension (1984) (3)
CARDIOVASCULAR COMPLICATIONS IN RELATION TO THE FRAMINGHAM RISK SCORE AND AGE IN HYPERTENSIVE PATIENTS WITH LVH: THE LIFE STUDY (2000) (3)
Cardiovascular outcomes at recommended blood pressure targets in middle-aged and elderly patients with type 2 diabetes mellitus and hypertension (2021) (3)
Behavioral consequences of hypertension and antihypertensive therapy. (1987) (3)
The importance of the sympathetic nervous system in hypertension. Introduction. (1999) (3)
On-treatment HDL cholesterol predicts incident atrial fibrillation in hypertensive patients with left ventricular hypertrophy (2020) (3)
Sympathetic overactivity in hypertension : A moving target : The sympathetic nervous system really is a key element in hypertension, with treatment implications (1996) (3)
Dissociation of the renin lowering and antihypertensive actions of propranolol. (1976) (2)
WITHDRAWAL OF ENDOGENOUS SYMPATHETIC DRIVE LOWERS BLOOD PRESSURE IN PRIMARY ALDOSTERONISM (1981) (2)
Aortic Root Dilatation in Hypertensive Patients with Left Ventricular Hypertrophy-Application of A New Multivariate Predictive Model. The Life Study. (2022) (2)
Discussion on the search for an ideal vasodilator: a hemodynamic perspective. (1987) (2)
SUDDEN CARDIAC DEATH IN RELATION TO CHANGING HEART RATE DURING TREATMENT OF HYPERTENSION: THE LIFE STUDY (2010) (2)
B018: Age-dependent event rate and reduction of coronary risk in hypertensive patients with LVH: The life study (2000) (2)
Development of systolic dysfunction unrelated to myocardial infarction in treated hypertensive patients with left ventricular hypertrophy. The LIFE Study (2022) (2)
Incident atrial fibrillation and heart failure in treated hypertensive patients with left ventricular hypertrophy. The LIFE Study (2022) (2)
Abstract 1881: Association of New-Onset Left Bundle Branch Block with Cardiovascular Morbidity and Mortality in Hypertensive Patients with Left Ventricular Hypertrophy: The LIFE study (2006) (2)
ARB clinical trials around the turn of the millennium (2000) (2)
“I1, imidazoline receptors: clinical relevance in hypertensive patients” : The role of sympathetic overactivity in the pathophysiology of cardiovascular diseases. (1999) (2)
A comparative study of several thiazides with special reference to the diuretic and anti-hypertensive effects of cyclothiazide. (1962) (2)
Methods for measuring vascular and nonvascular alpha-receptor sensitivity in humans. (1985) (2)
Angiotensin converting enzyme inhibitors and the progress of antihypertensive therapy. (1989) (2)
106 Failure to develop established hypertension with repeated neurogenic pressor episodes (1988) (2)
Task Force 4: Behavioral consequences of hypertension and antihypertensive therapy (1987) (2)
776 BLOOD PRESSURE MEASUREMENT DEVICE, NUMBER AND TIMING OF VISITS, AND INTRA-INDIVIDUAL STANDARD DEVIATION OF BLOOD PRESSURE (2012) (2)
Prehypertension in China. (2009) (2)
Patterns of neurogenic involvement in borderline and essential hypertension. (1977) (2)
EFFECT OF NATURALLY RANDOM ALLOCATION TO LOWER BLOOD PRESSURE BEGINNING BEFORE THE DEVELOPMENT OF HYPERTENSION (2013) (2)
Bringing VALUE to LIFE (2003) (2)
PREDICTORS OF STROKE RECURRENCE IN HIGH-RISK, HYPERTENSIVE PATIENTS: 3B.01 (2010) (2)
Changes in left ventricular diastolic filling during the development of left ventricular hypertrophy (1990) (2)
Relationship of renin status to adrenergic vascular tone in borderline hypertension (1974) (1)
Reply to Visit‐to‐Visit Blood Pressure Variation: Time to Reanalyze All The Data From the TROPHY Study (2013) (1)
P-485: High normal blood pressure and co-morbidity in the TROPHY study (2002) (1)
Left Atrial Systolic Force in Hypertensive Patients with Left Ventricular Hypertrophy-: A Predictor of Incident Atrial Fibrillation. The LIFE Study (2021) (1)
Incident left bundle branch block predicts cardiovascular events and death in hypertensive patients with left ventricular hypertrophy. The LIFE Study (2022) (1)
P-453 *Program Revision (see p. 267A): Gender specific characteristics of 15,288 hypertensive patients at high coronary risk. The value trial (2001) (1)
Electrocardiographic strain pattern and the prediction of cardiovascular morbidity and mortality in hypertensive patients: The LIFE study (2003) (1)
The Therapeutic Dilemma of Hypertension in the Elderly (2012) (1)
E3 - Effects of physiological epinephrine on platelet function and haematocrit in young men (1995) (1)
OR-21: Relation of serum uric acid to cardiovascular endpoints in hypertension: the life study (2003) (1)
O-30: Predictors of cardiovascular events in 9,194 hypertensive patients with left ventricular hypertrophy. The LIFE study* (2001) (1)
Relationship of tachicardia with high blood pressure and metabolic abnormalities. A study mixture analysis in four Western and two African populations (1997) (1)
Clinical Outcome Trials of Hypertension with Angiotensin Receptor Blockers (2005) (1)
Does life-long reduction in low-density lipoprotein cholesterol reduce the risk of new-onset hypertension? (2006) (1)
RACIAL DIFFERENCES IN SUDDEN CARDIAC DEATH AMONG HYPERTENSIVE PATIENTS DURING ANTIHYPERTENSIVE THERAPY: THE LIFE STUDY (2011) (1)
Predictors of cardiac morbidity in diabetic, new-onset diabetic and non-diabetic high-risk hypertensive patients: The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial (2016) (1)
Association of Left Ventricular Hypertrophy Regression and Heart Rate Reduction With Determinants of Myocardial Oxygen Consumption and Cardiovascular Events: The LIFE Study (2003) (1)
A Point System Table to Estimate the Risk of Cardiovascular Events in Patients with Hypertension and Left Ventricular Hypertrophy: The LIFE Study (2021) (1)
TIME-VARYING SERUM URIC ACID PREDICTS NEW-ONSET ATRIAL FIBRILLATION IN TREATED HYPERTENSIVE PATIENTS (2022) (1)
The Importance of Prompt Blood Pressure Control to Target in High Risk Hypertensive Patients: The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial (2004) (1)
Ambulatory Blood Pressure Monitoring (ABPM) in the VALUE Trial (2005) (1)
Prehypertension: Definitions, Clinical Significance and Therapeutic Approaches—To Treat or not to Treat? (2012) (1)
Establishing Targets for Hypertension Control in Patients with Comorbidities (2010) (1)
Decreased total peripheral resistance accounts for the initial hypotensive action of timolol (1982) (1)
Borderline hypertension. (1983) (1)
Is urinary albumin excretion an independent predictor of cardiovascular mortality in patients with electrocardiographic left ventricular hypertrophy? The LIFE study (2002) (1)
CARDIAC REMODELING AND DIASTOLIC DYSFUNCTION PRECEDE NON MI-RELATED HEART FAILURE IN HIGH-RISK HYPERTENSIVE PATIENTS: THE LIFE ECHO SUBSTUDY. (2010) (1)
Preventive cardiology: abstractCardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy. The LIFE study (2004) (1)
Quality of life during antihypertensive treatment. Refining its measurement to individualize drug selection. (1988) (1)
Challenging the paradigm for treatment of hypertension: Focus on elevated systolic blood pressure: Introduction (1999) (1)
[OP.8B.03] COFFEE IS A PREDICTOR OF FUTURE HYPERTENSION AND MICROALBUMINURIA IN TROPHY STUDY OF PREHYPERTENSION (2017) (1)
History of Prehypertension: Past and Present, a Saga of Misunderstanding and Neglect (2018) (1)
Psychophysiologic Evidence for the Role of the Nervous System in Hypertension (1982) (1)
CHARACTERISTICS OF REVERSED OFFICE HYPERTENSION - MAY TREATMENT RESISTANT HOME HYPERTENSION BE EXPLAINED BY SMOKING?: 4A.5 (2004) (1)
888-2 Does left ventricular hypertrophy predict sudden cardiac death independent of ischemia? The LIFE study (2004) (1)
ACE inhibition: More than just blood pressure reduction - Introduction (2001) (0)
ALLHAT Revisited: How Have the Findings Held Up 5 Years Later? (2007) (0)
Trial finds valsartan and amlodipine equally effective for preventing cardiac disease among people with hypertension at high risk. (2004) (0)
Vascular effects of alpha-receptors in hypertension (1995) (0)
[OP.4A.01] SYSTOLIC VISIT-TO-VISIT BLOOD PRESSURE VARIABILITY INCREASES RISK OF MYOCARDIAL INFARCTION AND CONGESTIVE HEART FAILURE IN PATIENTS GIVEN VALSARTAN OR AMLODIPINE IN THE VALUE TRIAL (2016) (0)
Abstract 3269: Association of Aortic Regurgitation with Cardiovascular Morbidity and Mortality in Hypertensive Patients with Left Ventricle Hypertrophy: The LIFE study (2007) (0)
Stroke outcomes in life (2003) (0)
Antihypertensive Therapy (1966) (0)
Methods for Measuring Vascular and Nonvascular α‐Receptor Sensitivity in Humans (1985) (0)
H015 Predictive power of heart rate for cardiovascular mortality in the elderly (1998) (0)
Role of arterial and cardiopulmonary receptors in regulation of renin release in man (1982) (0)
The Treatment of Hypertension (1962) (0)
PREDICTORS OF CARDIAC MORBIDITY IN DIABETIC, NEW-ONSET DIABETIC AND NON-DIABETIC HIGH-RISK HYPERTENSIVE PATIENTS: THE VALUE TRIAL: 5A.03 (2010) (0)
MENTAL STRESS IN LABILE HYPERTENSION (1969) (0)
Coronary heart disease: Interdisciplinary Council on reducing the risk: Introduction (2002) (0)
Abstract 3267: Gender Difference in the Association of Aortic Valve Sclerosis and Cardiovascular Events in Hypertensive Adults with Left Ventricular Hypertrophy: The LIFE Study (2007) (0)
Should prehypertension be treated with antihypertensive drugs (2007) (0)
AT1 blockers: are there alternative pathways reducing cardiovascular risk? Introduction. (2002) (0)
PS 14-44 FEASIBILITY OF REGRESSION OF HYPERTENSION USING CONTEMPORARY ANTIHYPERTENSIVE MEDICATIONS (2016) (0)
New clinical trials of angiotensin blockade in cardiovascular disease: foreword. (2000) (0)
Solvay Symposium: 3rd Cardiovascular Disease Prevention Meeting, London, UK, 7 February 1997: Introduction (1997) (0)
hypertension (LIFE) study of atrial fibrillation: The Losartan Intervention For End point reduction in Cardiovascular morbidity and mortality in hypertensive patients with a history (2011) (0)
Therapeutic decisons in management of borderline hypertension (1983) (0)
P-579: Relationship of sympathetic tone and beta adrenoreceptor responsiveness to blood pressure and overweight (2001) (0)
D16 - Hypertension optimal treatment study: Predictors of response to treatment in the U.S. Cohort (1995) (0)
DETERMINANTS OF THE TIME COURSE OF LVH-REGRESSION: THE VALUE-TRIAL (2004) (0)
Hematocrit: The relationship to cardiovascular risk in two generations (2000) (0)
Obituary – Björn Folkow (2012) (0)
Invited review Atrial fibrillation and hypertension (2009) (0)
Abstract P221: Cardiovascular Outcomes In Hypertensive Patients Who Discontinue Study Medication In A Large Outcome Trial. The Life Study. (2022) (0)
Impact of Diabetes Mellitus on Regression of Electrocardiographic Left Ventricular Hypertrophy and the Prediction of Outcome During Antihypertensive Therapy The Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study Hypertension (2006) (0)
Neuroendocrine Factors: Role of Sympathetic Nervous and Renin Angiotensin Systems (2000) (0)
Familial hyperlipoproteinemic syndromes. (1966) (0)
Practical management of borderline hypertension. (1980) (0)
[Latent hypertension]. (1972) (0)
CARDIOVASCULAR OUTCOMES AT RECOMMENDED BLOOD PRESSURE TARGETS IN MIDDLE AGED AND ELDERLY PATIENTS WITH TYPE 2 DIABETES MELLITUS AND HYPERTENSION (2021) (0)
Phenotypic Changes in the Transition from Prehypertension to Established Hypertension (2018) (0)
LONG-TERM PLASMA CATECHOLAMINES IN PATIENTS WITH HYPERTENSION LEFT VENTRICULAR HYPERTROPHY TREATED WITH LOSARTAN OR ATENOLOL. ICARUS, A LIFE SUBSTUDY: P1.92 (2004) (0)
Abstract 5862: Development of Systolic Dysfunction Not Related to Myocardial Infarction in Treated Hypertensive Patients With Left Ventricular Hypertrophy: The LIFE Echo Substudy (2009) (0)
Abstract 9199: Racial Differences in Incident Atrial Fibrillation Among Hypertensive Patients During Antihypertensive Therapy: The LIFE Study (2010) (0)
Expression of concern (2018) (0)
Left atrial systolic force in hypertensive patients with left ventricular hypertrophy predicts atrial fibrillation (2022) (0)
EFFECTS OF SINGLE OR MULTIPLE DRUG THERAPIES ON CARDIOVASCULAR OUTCOMES IN HYPERTENSION: ANALYSIS OF DATA FROM THE VALUE TRIAL: 6C.04 (2011) (0)
I9 - Home blood pressure is and overweight is not a reliable predictor of hypertension (1995) (0)
The Role of the Sympathetic Nervous System in Hypertension: Facts and Fallacies (1996) (0)
Long-term plasma catecholamine levels in patients with hypertension and left ventricular hypertrophy treated with losartan or atenolol. Icarus, a life substudy (2004) (0)
Normative Data on Blood Pressure Self-determination (2017) (0)
Unmet needs in the treatment of hypertension : Clinical significance of borderline hypertension. (1999) (0)
1085-166 Does hormone replacement therapy in women influence their benefit of losartan-treatment in the LIFE study? (2004) (0)
P-240: Utility of blood pressure during submaximal exercise in the risk stratification of patients with high normal blood pressure (2002) (0)
INFLAMMATORY MARKER IN PREHYPERTENSION ARE ASSOCIATED WITH BODY MASS BUT NOT WITH BLOOD PRESSURE TRENDS: HT.2.01 (2010) (0)
The LIFE sudy (2005) (0)
P-21: Effect of perindopril erbumine, an angiotensin converting enzyme inhibitor (ACE-I), in the treatment of 1022 African-American patients with mild to moderate hypertension: subgroup analysis of a 12 week, open-label, Aceon®Community Trial (ACT) (2002) (0)
Continuing on J.P. Henry's path; studies of physiology and pathophysiology of cardiopulmonary receptors in humans. (1997) (0)
Metabolic syndrome and insulin resistance in the trophy sub-study: contrasting views in high normal blood pressure (2004) (0)
Abstract 3617: The Relation of New Atrial Fibrillation to Cardiovascular and All-Cause Mortality During Treatment of Hypertension: The LIFE Study (2007) (0)
Book reviews (2008) (0)
Abstract 5419: Hypokalemia Blunts Left Ventricular Mass Regression in Hypertensive Patients During Losartan- or Atenolol-Based Treatment: The LIFE Echo-substudy (2009) (0)
THE SHORT TREATMENT WITH THE ANGIOTENSIN RECEPTOR BLOCKER CANDESARTAN SURVEYED BY TELEMEDICINE (STAR CAST) STUDY: STUDY RATIONALE AND INTERIM REPORT: HT.2.02 (2010) (0)
The Role of the Brain in Prehypertension (2018) (0)
D012 Valsartan antihypertensive longterm use evaluation (the value study) (1998) (0)
P-523: Leptin is associated with insulin resistance and impaired small artery distensibility in subjects with high normal blood pressure (2002) (0)
Ethnicity, left ventricular hypertrophy regression and cardiovascular events in the life echocardiography substudy (2004) (0)
Sympathetic nervous system overactivity as a contributor to cardiovascular morbidity : satellite symposium to the 3rd Cardiovascular Disease Prevention Meeting, London, UK, 7 February 1997 (1997) (0)
Dr Lowe has received funding for investigator-initiated (2002) (0)
Hypertensive patients with diabetes have less regression of electrocardiographic left ventricular hypertrophy in response to antihypertensive therapy: The LIFE study (2003) (0)
Abstract 10123: Evidence Against the J-shaped Curve in Treated Hypertensive Patients With Increased Cardiovascular Risk: The VALUE Trial (2015) (0)
ISH 2012 AWARDS AND PRIZES & COUNCIL 2012 (2012) (0)
MANAGING THE CARDIOVASCULAR RISKS IN HYPERTENSION Introduction (2003) (0)
Correlates of plasma renin activity pra in man (1987) (0)
OR-32: Clinical experience with perindopril, an angiotensin converting enzyme inhibitor (ACEI), in U.S. hypertensive patients - a large community-based trial (2003) (0)
HYPOKALEMIA BLUNTS LEFT VENTRICULAR MASS REGRESSION IN HYPERTENSIVE PATIENTS DURING LOSARTAN- OR ATENOLOL-BASED TREATMENT: THE LIFE ECHO-SUBSTUDY: 9D.06 (2010) (0)
IMPORTANCE OF MEAN BLOOD PRESSURE AND BLOOD PRESSURE VARIABILITY FOR THE EFFECT OF VALSARTAN VERSUS AMLODIPINE ON CARDIOVASCULAR EVENTS AND DEATH (2018) (0)
Increased alpha adrenergic stimulation on beta inhibitor therapy in hypertension (1977) (0)
P-225: Predictors of one year blood pressure control and treatment resistance in the value trial (2002) (0)
D7 - The “hot” study; a large international prospective trial to evaluate the “J” curve during treatment of hypertension (1995) (0)
Comparison of the results of the two series of experiments shows that vasoconstriction of the mesenteric vessels in response to stimulation of the celiac ganglion took place against (1982) (0)
Antihypertensive Utility of Perindopril in a Large, General Practice‐Based Clinical Trial (2005) (0)
S-10-3: CAN ACHIEVED AVERAGE SYSTOLIC BLOOD PRESSURE BELOW 130 MMHG CAUSE HARM IN ELDERLY HYPERTENSIVE PATIENTS WITH LEFT VENTRICULAR HYPERTROPHY? (2023) (0)
B017: The valsartan antihypertensive longterm use evaluation (VALUE) trial: Final patients demographics (2000) (0)
Blood pressure elevation during hindlimb compression in dogs is neurogenic (1982) (0)
Coronary risk in hypertension. A problem for young and old patients (1995) (0)
Impact of diabetes development on atrial fibrillation in hypertensive patients (2008) (0)
Expression of concern (2018) (0)
Wednesday, 5/17, Trianon, 8:30 am–11:30 am Unresolved Issues in the Treatment of HypertensionTHE “HOT” STUDY:US VERSUS THE WORLD EXPERIENCES (1995) (0)
Are left ventricular mass, geometry, and function related to vascularchanges and/or insulin resistance in longstanding hypertension? A LIFE substudy (2002) (0)
Use of clonidine and propranolol as monotherapy in borderline hypertension. (1983) (0)
The hypertension optimal treatment (hot) study — Home BP in treated hypertensives (1997) (0)
S-52-1: CARDIOVASCULAR OUTCOMES IN HYPERTENSIVE PATIENTS WHO DISCONTINUE STUDY MEDICATION IN A LARGE OUTCOME TRIAL. THE LIFE STUDY. (2023) (0)
From TROPHY with pride. (2007) (0)
Assessment Of Autonomic Function in Essential Hypertension (1986) (0)
Summary of 1993 WHO/ISH guidelines for the management of mild hypertension: memorandum from a WHO/ISH meeting. Guidelines Sub-Committee of WHO/ISH Mild Hypertension Liaison Committee. (1993) (0)
The hemodynamics of borderline hypertension (1989) (0)
Chapter 31 – The LIFE Study (2005) (0)
THE EFFECT OF BASELINE PHYSICAL ACTIVITY ON CARDIOVASCULAR OUTCOMES IN PATIENTS TREATED FOR HYPERTENSION AND LEFT VENTRICULAR HYPERTROPHY: P3.323 (2004) (0)
The effect of baseline physical activity on cardiovascular outcomes in patients treated for hypertension with LVH. (2004) (0)
Wednesday, May 16, 4:00 PM to 6:00 PM Sympathetic Nervous System, I1 Imidazoline Receptors, Hypertension and Metabolic Disorders*: Diabetes: The benefits of blood pressure and metabolic control in hypertension* (2001) (0)
Management of Prehypertension: Current Status and Future Strategies (2011) (0)
DOWNREGULATION OF BETA-ADRENOCEPTOR MEDIATED THERMOGENIC RESPONSES FACILITATES WEIGHT GAIN IN HYPERTENSION: P1.173 (2004) (0)
Atrial fibrillation and hypertension (2009) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Stevo Julius?

Stevo Julius is affiliated with the following schools:

Stevo Julius's Academic­Influence.com Rankings

Why Is Stevo Julius Influential?

Stevo Julius's Published Works

Published Works

What Schools Are Affiliated With Stevo Julius?

Stevo Julius's AcademicInfluence.com Rankings